Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.



Nestle raises stake in food allergy drug developer Aimmune

Nestle raises stake in food allergy drug developer Aimmune
A Nestle logo is pictured on a coffee factory in Orbe, Switzerland May 31, 2018. Picture taken May 31, 2018. REUTERS/Denis Balibouse -
Text size Aa Aa

(Reuters) - The health science arm of Nestle SA <NESN.S> will pay $98 million (76 million pounds) to raise its stake in Aimmune Therapeutics <AIMT.O>, as the drug developer prepares to submit a marketing application for its peanut allergy treatment by the end of the year.

Following the deal, which gives Nestle a stake of about 19 percent in Aimmune, Nestle would have invested $273 million in the company.

The companies also extended their two-year strategic collaboration to develop therapies for food allergy by another two years, Aimmune said.

In the United States, there is no approved treatment for peanut allergies, a medical condition that is becoming increasingly common and could be fatal.

With its oral drug, AR101, Aimmune hopes to be one of the first companies with a treatment on the market.

The investment finances Aimmune "well beyond" the anticipated approval and launch of the drug in the United States, Chief Executive Officer Jayson Dallas said in a statement.

Nestle Health Science first invested $145 million in Aimmune in 2016, followed by $30 million as part of the company's public offering in February 2018.

Nestle's per share price of $30.27 is slightly below Aimmune's close on Friday at $30.29. The companies expect to close the equity investment by the end of 2018.

(Reporting by Tamara Mathias in Bengaluru)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.